Oncology Indications Can Be Cellular Targets Rather Than Organs, FDA Says
Executive Summary
Cancer therapies can be indicated for tumors defined by cellular markers rather than conventional organ-specific targets, FDA Oncology Drug Products Division Director Richard Pazdur, MD, said during the American Society of Clinical Oncology annual meeting in New Orleans June 5
You may also be interested in...
Cancer Drugs Will Follow AIDS “Cocktail” Model, ASCO Researchers Say
Cancer treatment will start following the HIV "cocktail" model, researchers said at the American Society of Clinical Oncology annual meeting in New Orleans
Cancer Drugs Will Follow AIDS “Cocktail” Model, ASCO Researchers Say
Cancer treatment will start following the HIV "cocktail" model, researchers said at the American Society of Clinical Oncology annual meeting in New Orleans
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Up-front spending on pharmaceuticals to treat colorectal cancer in the U.S. would be $7.5 bil. per year if oncologists use newly launched therapies without restrictions, Memorial-Sloan Kettering Cancer Center researcher Leonard Saltz, MD, told the American Society of Clinical Oncology annual meeting June 5 in New Orleans